Глава 20
1. Csapo A.I., Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet. Gynecol. Surv. 1978; 33: 69–81.
2. Nováková L, Blanková B. {0}VIII. Reproductive Systems. 1. Female Reproductive System, Pregnancy and Childbirth. В: Functions of Cells and Human Body. http://fblt.cz/en/skripta/viii-rozmnozovaci-soustavy/1-zenske-pohlavni-organy-tehotenstvi-a-porod/.
3. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8 (Suppl 1): 3–63.
4. Di Renzo G.C., Mattei A., Gojnic M., Gerli S. Прогестерон и беременность. Curr Opin Obstet Gynecol. 2005; 17(6): 598–600.
5. Griesinger G., Herman Tournaye, Nick Macklon, Felice Petraglia, Petra Arck, Christophe Blockee, Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction // RBMO. 2019. Vol. 38, Issue 2. P. 249–259.
6. Мedawar P.B. Nobel lecture 1960 г.: Immunological tolerance. Доступно на http://www.nobelprize.org/nobel_prizes/medicine/laureates/1960/medawar-lecture.html [Google Scholar].
7. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., Szereday L. Progesterone as an immunomodulatory molecule. Int. Immunopharmacol. 2001; 1: 1037–1048.
8. Mao G., Wang J., Kang Y., Tai P., Wen J., Zou Q., Li G., Ouyang H., Xia G., Wang B. Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology 2010; 151: 5477–5488. doi: 10.1210/en.2010-0426.
9. Engler J.B., Kursawe N., Solano M.E., Patas K., Wehrmann S., Heckmann N., Luhder F., Reichardt H.M., Arck P.C., Gold S.M., Friese M.A. Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. Proc. Natl. Acad. Sci. U. S. A. 2017; 114: E181–E190. doi: 10.1073/pnas.1617115114.
10. Areia A., Vale-Pereira S., Alves V., Rodrigues-Santos P., Moura P., Mota-Pinto A. Membrane progesterone receptors in human regulatory T cells: a reality in pregnancy. BJOG. 2015; 122: 1544–1550. doi: 10.1111/1471-0528.13294.
11. Dosiou C., Hamilton A.E., Pang Y., Overgaard M.T., Tulac S., Dong J., Thomas P., Giudice L.C. Expression of membrane progesterone receptors on human T lymphocytes and jurkat cells and activation of G-proteins by progesterone. J. Endocrinol. 2008; 196: 67–77. doi: 10.1677/JOE-07-0317.
12. Blois S.M., Ilarregui J.M., Tometten M., Garcia M., Orsal A.S., Cordo-Russo R., Toscano M.A., Bianco G.A., Kobelt P., Handjiski B., Tirado I., Markert U.R., Klapp B.F., Poirier F., Szekeres-Bartho J., Rabinovich G.A., Arck P.C. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 2007; 13: 1450–1457. doi: 10.1038/nm1680.
13. Griesinger G., Blockeel C., Sukhikh G.T., Patki A., Dhorepatil B., Yang D.Z., Chen Z.J., Kahler E., Pexman-Fieth C., Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in in vitro fertilization: a randomized clinical trial. Hum. Reprod. 2018; 33: 2212–2221. doi: 10.1093/humrep/dey306.
14. Krey G., Frank P., Shaikly V., Barrientos G., Cordo-Russo R., Ringel F., Moschansky P., Chernukhin I.V., Metodiev M., Fernandez N., Klapp B.F., Arck P.C., Blois S.M. In vivo dendritic cell depletion reduces breeding efficiency, affecting implantation and early placental development in mice. J. Mol. Med. (Berl.) 2008; 86: 999–1011. doi: 10.1007/s00109-008-0379-2.
15. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е. Акушерство: национальное руководство. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018. 1088 с.
16. ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open. 2020: hoaa009. https://doi.org/10.1093/hropen/hoaa009 PMID: 32395637.
17. Practice Committee of the American Society for Reproductive Medicine. Current clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril 2015; 103: e27–e32.
18. Edwards R.G., Steptoe P.C., Purdy J.M. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br. J. Obstet. Gynaecol. 1980; 87: 737–756.
19. Fatemi H.M. Assessment of the luteal phase in stimulated and substituted cycles. Facts, views & vision in ObGyn. 2009; 1: 30–46.
20. Fauser B.C., Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol. Metab. 2003; 14: 236–242.
21. Barbosa M.W.P., Silva L.R., Navarro P.A. et al. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016; 48: 161–170.
22. Kolibianakis E.M., Venetis C.A., Papanikolaou E.G., Diedrich K., Tarlatzis B.C., Griesinger G. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Human Reprod. 2008; 23(6): 1346: 1354–710.